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Abstract
Background: Neurofibroma occurs as isolated or multiple lesions frequently associated with neurofibromatosis
type 1 (NF1), a common autosomal dominant disorder affecting 1 in 3500 individuals. It is caused by mutations in
the NF1 gene, which comprises 60 exons and is located on chromosome 17q11.2. NF1 is a fully penetrant gene
exhibiting a mutation rate some 10-fold higher compared with most other disease genes. As a consequence, a
high number of cases (up to 50%) are sporadic. Mutation detection is complex due to the large size of the NF1
gene, the presence of pseudogenes and the great variety of lesions.
Methods: 110 patients with at least two neurofibroma lesions recorded in the files of the Pathology Department
of the University of Modena during the period 1999-2010, were included in this study. Through interviews and
examination of clinical charts, pedigrees were drawn for all patients who were affected by at least two
neurofibromas. We attempted to delineate the clinical features of NF1 and the mutational spectrum in the cohort
of 11 NF1 families identified. For each proband, the whole coding sequence and all splice sites were studied for
mutations, either by the protein truncation test (PTT), or, more frequently, by denaturing high performance liquid
chromatography (DHPLC). Two GIST tumors of NF1 patients were tested for somatic NF1 mutations.
Results: NF1 germline mutations were identified in 7 (68%) patients. A novel mutation, c.3457_3460delCTCA in
exon 20, was detected in two unrelated patients and was associated with different clinical features. No NF1
somatic mutations were detected in the GIST tumors. A wide phenotypic and genotypic variability was registered,
both in the spectrum of skin lesions and visceral neoplasms, even among members of the same family who had
different clinical manifestations. A proclivity to multiple tumors arising in the same subject, and a higher tumor
burden per family were the most relevant findings observed in patients affected with the NF1 mutation.
Conclusions: We report a novel NF1 mutation and we contribute data for the refinement of the NF1 genotype-
phenotype spectrum.
Background
Neurofibroma is a benign peripheral nerve sheath tumor
composed of a variable mixture of Schwann, perineurial-
like, and fibroblastic cells that occurs sporadically as
well as in conjunction with neurofibromatosis type 1
(NF1) [1-3]. The 50% of patients affected by neurofibro-
mas have no family history of the disease; their NF1 is
sporadic and usually results from a new mutation in the
germ cell of one of the parents. NF1 (MIM# 162200),
also called von Recklinghausen disease or peripheral
neurofibromatosis, is one of the most common autoso-
mal dominant disorders, with virtually 100% penetrance
by adulthood. The prevalence of NF1 is about 1 in 3,500
live births [4]. Diagnosis is based on the clinical criteria
recommended by an NIH Consensus Conference [5],
which include multiple café-au-lait spots (CLS), cuta-
neous or subcutaneous neurofibromas, plexiform neuro-
mas, axillary or inguinal freckling, optic gliomas, and iris
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any medium, provided the original work is properly cited.Lisch nodules. Although the three characteristic features
(CLS, neurofibromas, and Lisch nodules) each occur in
over 90% of all NF1 patients by puberty, the number of
lesions is extremely variable. Approximately 30-40% of
NF1 patients may develop larger and more complex
plexiform neurofibromas associated with major nerve
trunks [6,7]. These congenital benign tumors often
develop in association with the major nerve tracts,
where they may involve multiple fascicles and branches
of the nerves [8].
NF1 patients are also predisposed to developing dys-
plastic skeletal lesions, learning difficulties or mental
retardation, myeloid leukemias and other malignancies,
and may exhibit vascular abnormalities and bone defor-
mities, thus implicating the NF1 gene in a wide variety
of tissues and disease processes [9,10].
The NF1 gene is located at 17q11.2, contains 60 exons
spanning approximately 350 kb of genomic DNA, and
encodes a 12-kb transcript [11] (GDB: 120231; Gen-
Bank: M82814). The gene product, neurofibromin, has
an estimated molecular weight of 327 kDa and is widely
expressed in many tissues. The mutation rate in the
NF1 gene is one of the highest reported in any human
disorder (approx. 1/10,000 gametes per generation) [12],
with approximately 50% of all NF1 patients having no
family history of the disease.
The objective of this study was both to evaluate
whether a combined clinical and biomolecular approach
could be useful for the identification of NF1 Syndrome
among a retrospective series of patients with a diagnosis
of multiple cutaneous neurofibroma and also to assess
the tumor spectrum and potential genotype-phenotype
correlation among an Italian cohort of NF1 patients.
Methods
In total, 331 surgically excised specimens of neurofibro-
mas from 110 patients affected by at least two neurofi-
bromas were retrospectivelyr e v i e w e db yc o n s u l t i n gt h e
archives of the Pathology Department of the University
of Modena from 1999 through 2010. The inclusion cri-
teria were: a) diagnosis of at least two neurofibromas
histologically confirmed; b) tumor tissue available for
microscopic analysis (glass slides and/or paraffin blocks);
c) medical records with demographic and clinical infor-
mation. Clinical data (anatomic distribution, gender, age,
multiple or isolated lesions, association with NF1, size
and duration) were extracted and tabulated. Through
interviews and examination of clinical charts, medical
pedigrees were drawn for all patients. Detailed family
histories were collected for each patient and/or their
relatives. Verification of cancer occurrence among family
members could be obtained for the majority of patients
through clinical charts, pathologic records or death cer-
tificates. The qualitative analysis of tumor microscopic
features was performed from routine sections stained
with hematoxylin-eosin (HeE). Through the reconstruc-
tion of the pedigree, we identified the families meeting
the consensus NIH clinical NF1 criteria [5].
Immunohistochemical analysis
For each patient, a representative paraffin-embedded
block was sectioned at 4 μm. Immunoperoxidase stain-
ing, using diaminobenzidine as chromogen, was run
with a Benchmark XT Automatic Staining System (Ven-
tana, Strasbourg, France). The slides were counter-
stained with hematoxylin. Rabbit polyclonal antibody
anti S-100 (Ventana, Strasbourg, France) was used pre-
diluted and MIB-1 mouse monoclonal antibody (anti
human Ki-67 antigen, Dako, Glostrup, Denmark) was
used at 1:200 dilution.
In addition, mouse monoclonal antibody anti EGFR
(clone 31G7, Ventana, Strasbourg, France) was used at a
dilution of 1:100 and mouse monoclonal antibody anti p53
(Cell Marque, Rocklin, CA, USA) at a dilution of 1:60.
Multiplex ligation-dependent probe amplification (MLPA)
analysis
Screening for the NF1 single and multi-exon deletions
was performed using the SALSA P081/082 NF1 V.04
MLPA assay (MRC-Holland, Amsterdam, The Nether-
lands), following the manufacturer’si n s t r u c t i o n s .T h i s
assay consists of two reaction mixtures containing
probes for all constitutive NF1 exons, with the exception
of exons 5, 7, 17, 19a, 45, and 47. An aliquot of ~100 ng
of denatured genomic DNA was used in the overnight
annealing of the exon-specific probes and subsequent
ligation reaction. PCR was carried out with FAM-labeled
primers using 10 μl of ligation reaction. Separation and
relative quantification of the amplification products
were carried out using a Beckman CEQ 2000XL. The
peak area for each fragment was measured and normal-
ized by dividing it by the combined area of all peaks in
that lane. This normalized peak area was then divided
by the average normalized peak area from five normal
controls. With this method, the results given are allele
copy numbers compared with normal controls, and a
ratio of ~1 should be obtained if both alleles are pre-
sent. A reduction or increase in the peak area values to
< 0.7 or > 1.3 was considered an indication of a deletion
or a duplication, respectively. DNA samples showing
such a reduction or increase in the MLPA peak area
values were reanalyzed by MLPA, and only the samples
showing consistent results between the two experiments
were considered positive for a deletion.
Germline mutation analysis of NF1 gene
Genomic DNA was extracted from the peripheral blood
of patients with neurofibromatosis type 1 (NF1) using
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cia, CA, USA), and stored at -20°C until use. All of the
NF1 exons were amplified by PCR with intron spanning
primers as described by De Luca et al. [13] and analyzed
with denaturing high-performance liquid chromatogra-
phy (DHPLC) as described elsewhere [14]. For each
abnormal elution profile, genomic DNA was directly
sequenced in both directions using a CEQ Dye-Termi-
nator Cycle Sequencing Kit (Beckman Coulter Inc.,
Miami, FL, USA) according to the manufacturer’s proto-
col. Mutations were checked using the Mutalyzer pro-
gram (http://www.LOVD.nl/mutalyzer).
Testing for somatic NF1 mutations in two GIST tumors
Two patients (no 5 and 6, table 1) developed a GIST
tumour. Paraffin-embedded primary tumor specimens of
each of their GISTs containing at least 70% tumor cells
were selected. For DNA isolation, five 10 μm sections of
tumor tissue were used and macrodissected using a
safety blade from the normal tissue, scraped off and col-
lected in an Eppendorf tube. Tissue sections were depar-
affinated with xilol and washed whith absolute ethanol.
Dna was isolated by a silica spin column-based method
with the QIAmp FFPE Tissue kit (Qiagne, Hilden, Ger-
many) according to the manufacturer’si n s t r u c t i o n s .
Mutation analysis was performed by direct sequencing
of 61 constitutive NF1 exons, in both directions, on a
3500 Genetic Analyzer (Applied Biosystems, Foster City,
CA) using primers as previously described(Ahiquist T.,
2008). Sequencing of coding exons and exon-intron
junctions were performed. Data were compared with the
mRNA reference sequence and with the chromosome
17 genomic contig reference sequence (NM_000267)
[15].
Real time PCR
DNA copy-number changes identified by MLPA were
confirmed using an ABI 7700 Sequence Detection Sys-
tem (Applied Biosystems) and the DNA-binding dye
SYBR Green (Applied Biosystems). To account for pos-
sible variations related to DNA input amounts or the
presence of PCR inhibitors, the reference gene MEFV
exon 5 was simultaneously quantified in a separate tube
for each patient sample. SYBR Green amplification mix-
tures (25 μl) contained SYBR Green master mix, 150
nmol/l of each forward and reverse primer, and 60 ng of
template DNA. The PCR cycling conditions were as fol-
lows: 2 min at 50°C, 2 min at 95°C, 40 cycles of 95°C
for 15 s and 60°C for 30 s, and a final step at 72°C for
30 s. After PCR amplification, a melting curve was gen-
erated for every PCR product to check the specificity of
the PCR (absence of primer dimers or other nonspecific
amplification products). Each assay included a no-tem-
plate control, 60 ng of a normal control DNA used as a
calibrator, and approximately 10 ng of test DNA (in tri-
plicate). Each sample was combined with two non-
deleted negative controls (in triplicate). The threshold
cycle (Ct) values of SDS software V.2.3 (Applied Biosys-
tems) were exported to Excel (Microsoft Corp., Seattle,
WA, USA) for further analysis. The ΔΔCt calculation
for the relative quantification of target was as follows:
  Ct = (Ct,target NF1 exon −Ct, MEFV)χ −(Ct, target NF1 exon −Ct, MEFV)y
where c is the unknown NF1 sample and y is the
calibrator.
Results for each sample were expressed in N-fold
changes in cNF1 gene copies, and normalized to MEFV
relative to the copy number of the NF1 gene in the cali-
brator according to the following equation [16]:
Amount of target = 2−  ct
A reduction in the peak area values to < 0.7 was con-
sidered an indication of a deletion.
Results
Clinical characterization and family history of all
patients (n 110 patients) were obtained. Familial NF1
was diagnosed in 11 of 110 patients who had at least
two neurofibromas (Figure 1; Table 1). All of the
remaining 99 patients were categorized with sporadic
cutaneous neurofibromas. The NF1 patients with a posi-
tive family history of neurofibromas and other skin
lesions typical of NF1 fulfille dt h ec r i t e r i af o rac l i n i c a l
diagnosis of NF1; this familial NF1 cohort included 95
patients (37 males and 58 females) who showed all skin
lesions characteristic of NF1, including café-au lait
macules, neurofibromas and peripheral nerve sheath
tumors (Figure 2, 3).
Most sporadic (64%) and most NF1-associated (53%)
neurofibromas were located in the supraclavicular bra-
chial plexus and the remainder were in an infraclavicu-
lar location. In patients affected by neurofibromas
associated with NF1, skin neurofibromas were often
multiple, synchronous, or metachronous, and they
were located preferentially in the brachial plexus (53%)
followed by the upper extremity (29%) and lower
extremity (18%). The average age at onset of the first
skin neurofibromas was 45.5 years (range, 14-86 years).
Cutaneous neurofibromas are found in the majority of
NF1 individuals, usually develop in the late teens or
early twenties but occasionally emerge in early child-
hood [17].
Clinically, the neurofibromas were soft, slightly ele-
vated, and rarely exceeded 2 cm in maximum dimension.
The neurofibromas in our sample developed in later life,
and only one patient confirmed that it was present at
birth. For all we examined all skin neurofibromas
Ponti et al. Hereditary Cancer in Clinical Practice 2011, 9:6
http://www.hccpjournal.com/content/9/1/6
Page 3 of 9resected surgically. Microscopically, neurofibromas were
formed by a combined proliferation of all elements of a
peripheral nerve: axons, Schwann’s cells, fibroblasts. In
the majority of cases, the predominant element was
Schwann’s cell, immunoreactive for S-100 protein. Mito-
sis was exceptional. The immunohistochemical analysis
of the examined neurofibromas showed absence of
expression of EGFR and p53 (Figure 4).
In the NF1 cohort patients, the average age at onset
of the first visceral malignancy was 52.3 years. The
tumor spectrum in the NF1 probands included adeno-
matous polyps, two colonic adenocarcinomas, two
Table 1 Clinical and biomolecular features of 11 patients with NF1 syndrome
Clinical features in the proband
Patient
N°
Gender,
(age in
yrs)
Germline mutation NFs (site) Café-au
lait
spots
Freckling Lisch
Nodules
Other clinical features NFs
andTumors in
the family
(age in yrs)
Proband
1
F (16) Absent NFs (chest) > 6 CAL Present Present None Father: NFs;
Liver (69);
Duaghter: NF1
Proband
2
F (64) Exon: 20
c.2093_2094delCT
p.(Pro698Argfs*3)
NFs (trunk,
face, limbs)
> 3 CAL Axillary
and
inguinal
N/A Multiple lipomas,
Adrenal adenoma, hepatic angioma,
inflammatory polyp of the bowel
Son: Cerebral
glioblastoma
(30)
Son: CAL, NFs
Proband
3
M (47) Exon: 4 c. 479 G >
C
p.(Arg160Thr)
NFs (trunk,
face)
> 6 CAL Absent Present Seminoma, adrenal adenoma Mother: Breast
cancer (59)
Proband
4
M (36) Exon 20
c.3457_3460delCTCA
p.(Leu1153Metfs*4)
NFs
(abdomen,
limbs, face)
> 6 CAL Axillary N/A Plexiform neurofibroma of the forehead,
orbito-sphenoid dysplasia, hearing loss,
oligophrenia
Mother: NFs;
Daughter: NFs
Aunt: Larynx
(68)
Cousin:
Pancreas (53)
Proband
5
M (50) Exon 6: large
deletion
NFs (Face,
Chest,
scalp)
> 6 CAL Axillary
and
inguinal
N/A Duodenal GIST, adenocarcinoma of the
colon
Mother: NFs;
Colon (70);
Brother: Colon
(59)
Uncle: NET (72)
Aunt: Lung
(52)
Proband
6
M (71) Exon 20
Del c 3457-3460del
CTCA
p.(Leu1153Metfs*4)
NFs (trunk,
face)
> 6 CAL Axillary N/A Duodenal GIST, adenocarcinoma of the
rectum
Mother: Renal
cell carcinoma
(75);
Sister: Renal
cell carcinoma
(49)
Proband
7
M (56) Exon 6
c.750delT
p.(Phe250Leufs*31)
NFs (trunk) > 6 CAL Axillary
and
inguinal
Present Plexiform neurofibroma of the sculp Brothers:NFs;
Lung (70); Son:
NFs;
Mother:NFs
Uncles:NFs
Aunt:NFs
Proband
8
F (33) Intron 46, c.8051-
70A > T
NFs (trunk
and limbs)
> 6 CAL Axillary Present Optic glioma Aunt: Lung
(72)
Proband
9
F (38) Not tested (proband
deceased)
NFs (chest,
limbs)
> 6 CAL Axillary None Ductal carcinoma in situ, Schwannoma. Cousin:NFs;
Ancle:NFs
Proband
10
F(70) Not tested (proband
deceased)
NFs (trunk,
limbs)
> 6 CAL Inguinal None None
Proband
11
F (41) Under investigation Absent > 6 CAL Absent N/A Ductal carcinoma (41) Daughter: > 6
CAL(4)
Grandfather:
NFs, ADK
colon (65)
Uncle: bown
sarcoma
NFs: Neurofibromas; NET: neuroendocrine tumor CAL: Café-au lait spots; N/A: information not available.
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breast tumor. Among first-degree affected relatives,
adenomatous polyps, cerebral glioblastoma, colon can-
cers, breast cancer and pancreatic cancer were detected
(Table 1).
Among the 11 NF1 probands, two GISTs and two col-
orectal carcinomas were found (Patients 5 and 6 in
Table 1). Histologically, the GISTs were predominantly
epithelioid consisting of mildly to moderately atypical
medium-sized polygonal cells. Both the GIST patients
had multiple cutaneous neurofibromas and more than
six pigmented macules ranging up to 1,5 cm in dia-
meter. One of them underwent left hemicolectomy for
T3N0M0 well differentiated adenocarcinoma of the rec-
tum at 43 years of age. Subsequently, a small tumor was
resected at the serosal side of the duodenum. Pathologic
examination showed GIST with very few mitoses (less
than 5 per 50 high power fields). He had a mother and
brother who were similarly affected by kidney cancer
(Figure 2). In NF1 families, a wide phenotypic and geno-
typic variability was evident, both in the spectrum of
skin lesions (neurofibromas, café-au-lait macules) and in
the type of visceral neoplasms. A great phenotypic varia-
bility was revealed, even among members of the same
family who had different clinical manifestations.
The results of the biomolecular analysis of 11 consent-
ing Italian patients with histologically confirmed multi-
ple neurofibromas, reported seven germline NF1
mutations (Table 1). The identified constitutional NF1
gene mutations ranged from single base pair substitu-
tions to gross deletions and the microlesions appeared
to be uniformly distributed across the gene. Two identi-
cal mutations (c.3457_3460delCTCA) in exon 20 were
associated with different clinical features in two
11 probands fullfilled the clinical NF1 criteria
(95 familial members)
99 patients were  considered sporadic 
(absence of additional  NF1-criteria).
110 patients with at least 2 neurofibromas
(331 cutaneous lesions)
7 of 11 probands presented NF1 germline mutations
2 NF1 patients not tested
2 NF1 proband under investigation
Figure 1 NF1 cases selected and the subsequent break-up in subcategories.
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multiple tumors arising in the same subject and a higher
tumor burden per family (Patients 4 and 6 in Table 1).
No somatic NF1 mutations were detected in GIST
neoplasms of patients 5 and 6 (Table 1).
Discussion
A combined clinicopathological and biomolecular
approach could be useful for the identification of NF1
Syndrome among patients with a diagnosis of multiple
cutaneous neurofibromas, starting with the evaluation of
retrospective pathological records. The majority of the
n e u r o f i b r o m a si nt h i ss e r i e sw e r es p o r a d i cn e u r o f i b r o -
mas not associated with NF1. These results clearly indi-
cate that most NF lesions develop as sporadic forms,
confirming the discriminatory role of an accurate family
history that should be viewed as the crucial step for a
proper diagnosis of neurofibromatosis type 1. In particu-
lar, the family history can be very helpful in making the
diagnosis in young children with only CAL spots, but
the role of the family history is limited as almost half of
all patients with NF1 are the first to be affected in their
families. Surgically treated benign and malignant
peripheral neural sheath tumors have been described in
a large series by Kim et al. [18] which showed that neu-
rofibromas were more often solitary lesions and not
associated with NF1. Our cut-off of at least two neurofi-
broma lesions as inclusion criteria represented a preli-
minary screening of patients affected by a solitary lesion
not usually associated with NF1. It is known that the
other 50% of patients affected by neurofibromas have no
family history of the disease; their NF1 is sporadic and
perhaps results from a new mutation in the germ cell of
one of the parents. Molecular biologists have observed
that about 90% of new NF1 mutations are paternally
d e r i v e d[ 1 9 ]a n ds o m es t u d ies have investigated the
hypothesis that older paternal age may increase the risk
for a new germinal NF1 mutation [20,21]. However, the
causes of sporadic neurofibromas not associated with
NF1 remain in part unclear. The trauma has been pro-
posed to trigger the formation of a neurofibroma
[22-24]. Yla-Outinen et al. [25] have demonstrated that
NF1 gene expression is up-regulated during wound heal-
ing in humans who do not have NF1.
In our NF1 patient cohort, a great phenotypic variabil-
ity was revealed both among unrelated patients and even
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Figure 2 Family pedigree of NF1 proband with GIST and neurofibromas cosegregating NF1 exon 20 germline mutation (c.3457_3460
del CTCA).
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clinical manifestations. However, besides the typical
cutaneous lesions, the tumor spectrum of our NF1
cohort included several gastrointestinal neoplasms. Of
interest, in two of the 11 NF1 unrelated probands
described in this report, we find the diagnosis of GIST.
Documented gastrointestinal manifestations of NF1
include neurofibromas, most commonly in the jejunum,
ganglioneuromatosis leading to disordered gut motility,
gangliocytic paragangliomas, periampullary duodenal
carcinoid tumors and GISTs [26,27]. The clinical asso-
ciation between GIST and type 1 neurofibromatosis has
been well characterized [28,29]. However, little is known
about the molecular basis underlying GIST development
in neurofibromatosis as well as in other syndromic set-
tings, and whether there is a difference in the molecular
pathogenesis of sporadic GISTs and GISTs associated
with multi-neoplastic disease.
Our research into the second, that is somatic, NF1
mutation in the GISTs of both probands carrying the
NF1 germline mutations started with the hypothesis that
the second somatic hit would appear to be an indepen-
dent event in each NF1-associated tumor. We did not
observe any somatic NF1 mutations in the two GIST
tumors studied, but our analysis would not have identi-
fied possibly relevant deep intronic NF1 mutations or
NF1 rearrangements. The somatic mutation spectrum of
the NF1 gene might be a crucial factor explaining the
variable clinical expression observed in NF1 patients.
Evaluation of additional NF1 patients with GIST is
necessary for better clarification of GIST pathogenesis
in the NF1 setting.
The identified germline NF1 gene mutations reflect
the wide genotypic variability ranging from single base
pair substitution to gross deletions and the microlesions
appeared to be uniformly distributed across the gene.
Until now, the genotype-phenotype relationship has not
been comprehensively studied in patients harboring NF1
mutations or large NF1 gene deletions.
Among our NF1 families, two identical mutations
(c.3457_3460delCTCA) in exon 20 (Patients 4 and 6 in
Table 1) did not cause similar clinical features in two
Figure 3 Clinical features of NF1 probands.
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rofibromas, developmental abnormalities, multiple CLS,
axillary freckling, duodenal GIST and rectal adenocarci-
noma, while the other had developmental delay, multi-
ple CLS and plexiform neurofibromas but had no GIST.
These observations suggest that disruption of the NF1
gene itself may not be enough to account for the clinical
variability and for the diverse NF1 phenotypes. Some
investigators have attempted to explain the variable clin-
ical expression seen in patients with identical germline
NF1 mutations. In the case of co-existing GIST and
other GI tumors, which mostly arise in the upper GI
tract, second NF1 somatic mutations might play a sig-
nificant role. Alternatively, inherited or epigenetic modi-
fiers, such as ethnicity or somatic aberrations in other
genes, may determine distinct clinical phenotypes. As
approximately half of the clinically diagnosed NF1 popu-
lation can be classified at the molecular level as having
neurofibromatosis type 1 (i.e. proven presence of a
germline mutation in NF1), there are most likely other
genomic regions that are also responsible for the disease
and it has been hypothesized that mutations in genes
other than NF1 may be necessary for the development
of the full phenotype. Some studies have evaluated the
role of EGFR and p53 genes in the pathogenesis of
malignant transformations of NF1 into MPNST: EGFR
and p53 were expressed in Schwann cells in 26% of
MPNST [30,31]. Our immunohistochemical evaluation
of neurofibromas does not show specific alterations of
the proteins codified by these two genes.
Conclusions
The clinical and pathological characterization of multi-
ple NF lesions may be used as screening for the identifi-
cation of families at risk of NF1. Our data indicate that
ap r o c l i v i t yt om u l t i p l et u m o r sa r i s i n gi nt h es a m es u b -
ject, and a higher tumor burden per family are the most
relevant findings observed in affected patients with the
NF1 mutation. Overall, the current findings indicate a
possible strategy that may be followed for the identifica-
tion and management of NF1 patients for which the
early diagnosis of abdominal manifestations is crucial
because of the risk of malignancy, organic complications
or hemorrhagic-obstructive complications such as in the
case of tumors of the gastrointestinal tract.
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